Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy

Nature Medicine

Volumn 16, Issue 7, 2010, Pages 774-780

  Wurtele, Hugo ^a   Tsao, Sarah ^a   Lépine, Guylaine ^a   Mullick, Alaka ^a,b   Tremblay, Jessy ^a,b   Drogaris, Paul ^a   Lee, Eun Hye ^a   Thibault, Pierre ^a   Verreault, Alain ^a   Raymond, Martine ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FUNGAL DNA; HISTONE H3; LYSINE; MICAFUNGIN; NICOTINAMIDE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL VIABILITY; CONTROLLED STUDY; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE CONTROL; GENE REPRESSION; GENOTOXICITY; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN TARGETING; STAINING;

ACETYLATION; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FUNGAL PROTEINS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; MICE; NIACINAMIDE; VIRULENCE;

CANDIDA ALBICANS;

EID: 77954541309     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2175     Document Type: Article

References (53)

1. Celic, I. et al. The sirtuins hst3 and Hst4p preserve genome integrity by controlling histone h3 lysine 56 deacetylation. Curr. Biol. 16, 1280-1289 (2006).
2. Masumoto, H., Hawke, D., Kobayashi, R. & Verreault, A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436, 294-298 (2005).
3. Hyland, E.M. et al. Insights into the role of histone H3 and histone H4 core modifable residues in Saccharomyces cerevisiae. Mol. Cell. Biol. 25, 10060-10070 (2005).
4. Ozdemir, A. et al. Characterization of lysine 56 of histone H3 as an acetylation site in Saccharomyces cerevisiae. J. Biol. Chem. 280, 25949-25952 (2005).
5. Xu, F., Zhang, K. & Grunstein, M. Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell 121, 375-385 (2005).
6. Zhou, H., Madden, B.J., Muddiman, D.C. & Zhang, Z. Chromatin assembly factor 1 interacts with histone H3 methylated at lysine 79 in the processes of epigenetic silencing and DNA repair. Biochemistry 45, 2852-2861 (2006).
7. Das, C., Lucia, M.S., Hansen, K.C. & Tyler, J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459, 113-117 (2009).
8. Tjeertes, J.V., Miller, K.M. & Jackson, S.P. Screen for DNA-damage-responsive histone modifcations identifes H3K9Ac and H3K56Ac in human cells. EMBO J. 28, 1878-1889 (2009).
9. Xie, W. et al. Histone h3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol. Cell 33, 417-427 (2009).
10. Yuan, J., Pu, M., Zhang, Z. & Lou, Z. Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle 8, 1747-1753 (2009).
11. Driscoll, R., Hudson, A. & Jackson, S.P. Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science 315, 649-652 (2007).
12. Han, J. et al. Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication. Science 315, 653-655 (2007).
13. Tsubota, T. et al. Histone H3-K56 acetylation is catalyzed by histone chaperone-dependent complexes. Mol. Cell 25, 703-712 (2007).
14. Maas, N.L., Miller, K.M., DeFazio, L.G. & Toczyski, D.P. Cell cycle and checkpoint regulation of histone H3 K56 acetylation by Hst3 and Hst4. Mol. Cell 23, 109-119 (2006).
15. Thaminy, S. et al. Hst3 is regulated by Mec1-dependent proteolysis and controls the S phase checkpoint and sister chromatid cohesion by deacetylating histone H3 at lysine 56. J. Biol. Chem. 282, 37805-37814 (2007).
16. Berman, J. & Sudbery, P.E. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat. Rev. Genet. 3, 918-930 (2002).
17. Cowen, L.E., Anderson, J.B. & Kohn, L.M. Evolution of drug resistance in Candida albicans. Annu. Rev. Microbiol. 56, 139-165 (2002).
18. Pfaller, M.A. & Diekema, D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
19. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
20. Sims, C.R., Ostrosky-Zeichner, L. & Rex, J.H. Invasive candidiasis in immunocompromised hospitalized patients. Arch. Med. Res. 36, 660-671 (2005).
21. Akins, R.A. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43, 285-318 (2005).
22. Perlin, D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10, 121-130 (2007).
23. Wang, L., Tang, Y., Cole, P.A. & Marmorstein, R. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr. Opin. Struct. Biol. 18, 741-747 (2008).
24. Frye, R.A. Phylogenetic classifcation of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793-798 (2000).
25. Kelly, J., Rowan, R., McCann, M. & Kavanagh, K. Exposure to caspofungin activates Cap and Hog pathways in Candida albicans. Med. Mycol. 47, 697-706 (2009).
26. Roemer, T. et al. Large-scale essential gene identifcation in Candida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50, 167-181 (2003).
27. Deere, D. et al. Flow cytometry and cell sorting for yeast viability assessment and cell selection. Yeast 14, 147-160 (1998).
28. Sudbery, P., Gow, N. & Berman, J. The distinct morphogenic states of Candida albicans. Trends Microbiol. 12, 317-324 (2004).
29. Haldar, D. & Kamakaka, R.T. Schizosaccharomyces pombe Hst4 functions in DNA damage response by regulating histone H3 K56 acetylation. Eukaryot. Cell 7, 800-813 (2008).
30. Xhemalce, B. et al. Regulation of histone H3 lysine 56 acetylation in Schizosaccharomyces pombe. J. Biol. Chem. 282, 15040-15047 (2007).
31. Mullick, A. et al. Dysregulated infammatory response to Candida albicans in a C5-defcient mouse strain. Infect. Immun. 72, 5868-5876 (2004).
32. Mullick, A. et al. Cardiac failure in C5-defcient A/J mice after Candida albicans infection. Infect. Immun. 74, 4439-4451 (2006).
33. Tuite, A., Elias, M., Picard, S., Mullick, A. & Gros, P. Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/6J mice. Genes Immun. 6, 672-682 (2005).
34. Maiese, K., Chong, Z.Z., Hou, J. & Shang, Y.C. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 14, 3446-3485 (2009).
35. Dizdaroglu, M. Base-excision repair of oxidative DNA damage by DNA glycosylases. Mutat. Res. 591, 45-59 (2005).
36. Bogan, K.L. & Brenner, C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130 (2008).
37. Niren, N.M. Pharmacologic doses of nicotinamide in the treatment of infammatory skin conditions: a review. Cutis 77, 11-16 (2006).
38. Cosgrove, M.S. et al. The structural basis of sirtuin substrate affnity. Biochemistry 45, 7511-7521 (2006).
39. Blander, G. et al. SIRT1 shows no substrate specifcity in vitro. J. Biol. Chem. 280, 9780-9785 (2005).
40. Garske, A.L. & Denu, J.M. SIRT1 top 40 hits: use of one-bead, one-compound acetyl-peptide libraries and quantum dots to probe deacetylase specifcity. Biochemistry 45, 94-101 (2006).
41. Saunders, L.R. & Verdin, E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26, 5489-5504 (2007).
42. Hirao, M. et al. Identifcation of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast. J. Biol. Chem. 278, 52773-52782 (2003).
43. Pfaller, M.A. et al. Results from the ARTEMIS Drosoph. Inf. Serv.K global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fuconazole and voriconazole determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48, 1366-1377 (2010).
44. Pappas, P.G. et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009).
45. Dagenais, T.R. & Keller, N.P. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin. Microbiol. Rev. 22, 447-465 (2009).
46. Kushnirov, V.V. Rapid and reliable protein extraction from yeast. Yeast 16, 857-860 (2000).
47. Gunjan, A. & Verreault, A.A. Rad53 kinase-dependent surveillance mechanism that regulates histone protein levels in S. cerevisiae. Cell 115, 537-549 (2003).
48. Poveda, A. et al. Hif1 is a component of yeast histone acetyltransferase B, a complex mainly localized in the nucleus. J. Biol. Chem. 279, 16033-16043 (2004).
49. Drogaris, P., Wurtele, H., Masumoto, H., Verreault, A. & Thibault, P. Comprehensive profling of histone modifcations using a label-free approach and its applications in determining structure-function relationships. Anal. Chem. 80, 6698-6707 (2008).
50. Schmitt, M.E., Brown, T.A. & Trumpower, B.L. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18, 3091-3092 (1990).
51. Tsao, S., Rahkhoodaee, F. & Raymond, M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53, 1344-1352 (2009).
52. Trunk, K. et al. Depletion of the cullin Cdc53p induces morphogenetic changes in Candida albicans. Eukaryot. Cell 8, 756-767 (2009).
53. Horsman, M.R., Siemann, D.W., Chaplin, D.J. & Overgaard, J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother. Oncol. 45, 167-174 (1997).